NCT01554917View on ClinicalTrials.gov

A Study of Iguratimod in Patients With Active Rheumatoid Arthritis

PHASE4CompletedINTERVENTIONAL
Enrollment

1,759

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Iguratimod

taken orally, 2 tablets/day (bid)

Trial Locations (1)

Unknown

Peking University People's Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Jiangsu Simcere Pharmaceutical Co., Ltd.

INDUSTRY

NCT01554917 - A Study of Iguratimod in Patients With Active Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter